Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 17/20 | 0.75 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.75 |
| ▸ | EED | O75530 | 2/20 | 0.75 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833828 | 0.92 | EZH2 (0.83) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833829 | 0.92 | EZH2 (0.83) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15824389 | 0.92 | EZH2 (0.83) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833760 | 0.90 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833792 | 0.90 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833759 | 0.90 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833831 | 0.87 | EZH2 (0.81) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833827 | 0.87 | EZH2 (0.81) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL15833832 | 0.87 | EZH2 (0.81) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL29352969 | 0.86 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | EZH2 1546/4885EZH1 1779/4885EED 2058/4885 |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | EZH2 1546/4885EZH1 1779/4885EED 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.